Our top pick for
Building a portfolio
QIAGEN N.V is a diagnostics & research business based in the US. QIAGEN N-V shares (QGEN) are listed on the NYSE and all prices are listed in US Dollars. QIAGEN N-V employs 5,324 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$36.16 - $59.00|
|50-day moving average||$53.06|
|200-day moving average||$51.22|
|Wall St. target price||$59.73|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing QIAGEN N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of QIAGEN N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
QIAGEN N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, QIAGEN N-V shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
QIAGEN N-V's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8204. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into QIAGEN N-V's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
QIAGEN N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $707.2 million.
The EBITDA is a measure of a QIAGEN N-V's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.9 billion|
|Operating margin TTM||27.25%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||5.71%|
|Return on equity TTM||13.47%|
|Market capitalisation||$10.9 billion|
TTM: trailing 12 months
There are currently 4.1 million QIAGEN N-V shares held short by investors – that's known as QIAGEN N-V's "short interest". This figure is 2.9% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting QIAGEN N-V shares can be evaluated.
QIAGEN N-V's "short interest ratio" (SIR) is the quantity of QIAGEN N-V shares currently shorted divided by the average quantity of QIAGEN N-V shares traded daily (recently around 963859.71563981). QIAGEN N-V's SIR currently stands at 4.22. In other words for every 100,000 QIAGEN N-V shares traded daily on the market, roughly 4220 shares are currently held short.
However QIAGEN N-V's short interest can also be evaluated against the total number of QIAGEN N-V shares, or, against the total number of tradable QIAGEN N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case QIAGEN N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 QIAGEN N-V shares in existence, roughly 20 shares are currently held short) or 0.0203% of the tradable shares (for every 100,000 tradable QIAGEN N-V shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against QIAGEN N-V.
Find out more about how you can short QIAGEN N-V stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like QIAGEN N-V.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 16.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and QIAGEN N-V's overall score of 16.36 (as at 12/31/2018) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like QIAGEN N-V is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.25/100
QIAGEN N-V's environmental score of 1.25 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 8.53/100
QIAGEN N-V's social score of 8.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 6.07/100
QIAGEN N-V's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that QIAGEN N-V is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. QIAGEN N-V scored a 1 out of 5 for controversy – the highest score possible, reflecting that QIAGEN N-V has managed to keep its nose clean.
|Total ESG score||16.36|
|Total ESG percentile||13.68|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||1|
We're not expecting QIAGEN N-V to pay a dividend over the next 12 months.
QIAGEN N-V's shares were split on a 962:1000 basis on 24 January 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 962 shares. This wouldn't directly have changed the overall worth of your QIAGEN N-V shares – just the quantity. However, indirectly, the new 4% higher share price could have impacted the market appetite for QIAGEN N-V shares which in turn could have impacted QIAGEN N-V's share price.
Over the last 12 months, QIAGEN N-V's shares have ranged in value from as little as $36.16 up to $59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while QIAGEN N-V's is 0.2839. This would suggest that QIAGEN N-V's shares are less volatile than average (for this exchange).
QIAGEN N. V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc. ; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.